



Secondary infection in severe and critical COVID-19 patients in China: a multicenter retrospective study

Ling Sang^{1,2#}, Yin Xi^{1#}, Zhimin Lin^{1#}, Ying Pan^{1#}, Bin Song^{3#}, Chang-an Li^{4#}, Xia Zheng⁵, Ming Zhong⁶, Li Jiang⁷, Chun Pan⁸, Wei Zhang⁹, Zheng Lv¹⁰, Jiaan Xia¹¹, Nanshan Chen¹², Wenjuan Wu¹³, Yonghao Xu¹, Sibe Chen¹, Dongdong Liu¹, Weibo Liang¹, Xuesong Liu¹, Xiaoqing Liu¹, Shiyue Li¹, Nanshan Zhong^{1,2}, Dan Ye⁴, Yuanda Xu^{1*}, Nuofu Zhang^{1*}, Dingyu Zhang^{14,15*}, Yimin Li^{1*}

¹State Key Laboratory of Respiratory Diseases, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Department of Pulmonary and Critical Care Medicine, Guangzhou, China; ²Guangzhou Laboratory, Jinyintan Hospital, Wuhan, China; ³Department of Tuberculosis and Respiratory Disease, Jinyintan Hospital, Wuhan, China; ⁴Department of Nosocomial Infection Management, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China; ⁵Department of Critical Care Medicine, The First Affiliated Hospital of Zhejiang University, Hangzhou, China; ⁶Department of Critical Care Medicine, Zhongshan Hospital Fudan University, Shanghai, China; ⁷Department of Critical Care Medicine, Xuanwu Hospital, Capital Medical University, Beijing, China; ⁸Department of Critical Care Medicine, Zhongda Hospital, Southeast University, Nanjing, China; ⁹Emergency Department, 900th Hospital of Joint Service Corps of Chinese PLA, Fuzhou, China; ¹⁰Department of Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; ¹¹Department of Tuberculosis, Wuhan Jinyintan Hospital, Wuhan, China; ¹²Department of Respiratory and Critical Care Medicine Wuhan Jinyintan Hospital, Wuhan, China; ¹³Department of Critical Care Medicine, Wuhan Jinyintan Hospital, Wuhan, China; ¹⁴Research Center for Translational Medicine, Wuhan Jinyintan Hospital, Wuhan, China; ¹⁵Joint Laboratory of Infectious Diseases and Health, Wuhan Institute of Virology and Wuhan Jinyintan Hospital, Chinese Academy of Sciences, Wuhan, China

Contributions: (I) Conception and design: Y Li, D Zhang, N Zhang, Y Xu; (II) Administrative support: Y Li; N Zhong, X Liu, S Li, D Ye; (III) Provision of study materials or patients: L Sang, B Song, Y Xi, Y Pan, Z Lin, C Li; (IV) Collection and assembly of data: L Sang, B Song, Y Xi, Y Pan, Z Lin, C Li, M Zhong, L Jiang, C Pan, W Zhang, Z Lv, N Chen, D Liu, W Liang; (V) Data analysis and interpretation: X Zheng, J Xia, W Wu, X Liu, C Li, Y Xu, S Chen; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

[#]These authors contributed equally to this work.

^{*}These authors contributed equally to this work as senior authors.

Correspondence to: Yimin Li, MD, PHD. State Key Laboratory of Respiratory Diseases, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Department of Pulmonary and Critical Care Medicine, 151 Yanjiang Road, Guangzhou 510120, China. Email: dryiminli@vip.163.com; Dingyu Zhang, MD, PHD. Wuhan Jinyintan Hospital, Research Center for Translational Medicine, Joint Laboratory of Infectious Diseases and Health, Wuhan Institute of Virology and Wuhan Jinyintan Hospital, Chinese Academy of Sciences, 1 Yintan Road, Dongxihu District, Wuhan 430023, Hubei, China. Email: 1813886398@qq.com; Nuofu Zhang, MD. State Key Laboratory of Respiratory Diseases, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Department of Respiratory Medicine, 151 Yanjiang Road, Guangzhou 510120, China. Email: nfzhanggird@163.com; Yuanda Xu, MD, PHD. State Key Laboratory of Respiratory Diseases, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Department of Pulmonary and Critical Care Medicine, 151 Yanjiang Road, Guangzhou 510120, China. Email: xuyuanda@sina.com.

Background: Since 2020 COVID-19 pandemic became an emergent public sanitary incident. The epidemiology data and the impact on prognosis of secondary infection in severe and critical COVID-19 patients in China remained largely unclear.

Methods: We retrospectively reviewed medical records of all adult patients with laboratory-confirmed COVID-19 who were admitted to ICUs from January 18th 2020 to April 26th 2020 at two hospitals in Wuhan, China and one hospital in Guangzhou, China. We measured the frequency of bacteria and fungi cultured from respiratory tract, blood and other body fluid specimens. The risk factors for and impact of secondary infection on clinical outcomes were also assessed.

Results: Secondary infections were very common (86.6%) when patients were admitted to ICU for >72 hours. The majority of infections were respiratory, with the most common organisms being *Klebsiella*

pneumoniae (24.5%), *Acinetobacter baumannii* (21.8%), *Stenotrophomonas maltophilia* (9.9%), *Candida albicans* (6.8%), and *Pseudomonas spp.* (4.8%). Furthermore, the proportions of multidrug resistant (MDR) bacteria and carbapenem resistant Enterobacteriaceae (CRE) were high. We also found that age ≥ 60 years and mechanical ventilation ≥ 13 days independently increased the likelihood of secondary infection. Finally, patients with positive cultures had reduced ventilator free days in 28 days and patients with CRE and/or MDR bacteria positivity showed lower 28-day survival rate.

Conclusions: In a retrospective cohort of severe and critical COVID-19 patients admitted to ICUs in China, the prevalence of secondary infection was high, especially with CRE and MDR bacteria, resulting in poor clinical outcomes.

Keywords: COVID-19; intensive care unit (ICU); secondary infection; carbapenem resistant Enterobacteriaceae (CRE); multidrug resistant *Acinetobacter baumannii*

Submitted Apr 08, 2021. Accepted for publication Jul 02, 2021.

doi: 10.21037/apm-21-833

View this article at: <https://dx.doi.org/10.21037/apm-21-833>

Introduction

Since December 2019, the coronavirus disease 2019 (COVID-19) pandemic has resulted in 127,619,612 laboratory-confirmed cases and 2,791,953 death cases worldwide up to March 31, 2021 (1). According to existing data, approximately 14–26% of hospitalized COVID-19 patients have needed treatment in an intensive care unit (ICU) (2,3), and the clinical outcomes of these cases has generally been poor, with the mortality rate reaching 61.5% within 28 days (4).

Secondary infection, including those caused by bacteria and fungi, may occur during the course of respiratory viral infection. The incidence of secondary infections during the 2009 influenza A (H1N1) pandemic was as high as 23% (5), and was found to cause poor clinical outcomes in critically ill patients (6). Over the past 20 years, although coronaviruses including severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV), and SARS-CoV-2, all of which mainly attack the lungs, have caused several outbreaks worldwide, the epidemiology of secondary infection during coronavirus epidemics still remains unknown. Only one single center retrospective study demonstrated that the presence of SARS-CoV in the ICU led to changes in the pattern of pathogens detected and increased the acquisition rate of multi-drug resistant *Staphylococcus aureus* (MRSA) (7). The long course of the disease and the immuno-suppressed state of severe and critical COVID-19 patients place them at high risk of secondary infection (8). Descriptive data found that 64.4% of hospitalized COVID-19 patients were

prescribed antibiotics (9) and this proportion in critically ill patients was as high as 97.5% (10). Unfortunately, until now the epidemiology of secondary infections in severe and critical COVID-19 patients admitted to the ICU remained largely unclear. Therefore, we performed a retrospective study to evaluate the incidence, risk factors and prognosis of secondary infection in severe and critical COVID-19 patients. We present the following article in accordance with the STROBE reporting checklist (available at <https://dx.doi.org/10.21037/apm-21-833>).

Methods

Patients

The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013). This study was approved separately by the Independence Ethics Committee of Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (Approval No. 2020-0307), Medical Ethics Committee of Wuhan Infectious Disease Hospital (Approval No. KY-2020-56.01) and Ethics Committee of the First Affiliated Hospital of Guangzhou Medical University (Approval No. 2020-065). Informed consent was waived due to the retrospective nature of the study.

We retrospectively reviewed medical records of all adult patients (>18 years) with laboratory-confirmed COVID-19 who were admitted to the ICU between January 18th 2020 and April 26th 2020 at two hospitals in Wuhan, China (Jinyintan Hospital and Union West Hospital) and one

hospital in Guangzhou, China (The First Affiliated Hospital of Guangzhou Medical University). All three hospitals were designated hospitals for COVID-19 patients. All patients met the criteria of having severe or critical COVID-19 according to the Chinese guidelines (11). The disease is defined as severe type if the patient met one of the following conditions: respiratory distress, respiratory rate ≥ 30 bpm or $\text{SPO}_2 \leq 93\%$ on room air or $\text{PaO}_2/\text{FiO}_2 \leq 300$ mmHg. The disease is defined as critical type if the patient met one of the following conditions: respiratory failure occurs and requires mechanical ventilation, shock, other organ dysfunction needing intensive care unit monitoring and treatment. The above two types of patients will be included in the analysis.

Data extraction

The clinical data, including patient demographics, comorbidities, laboratory findings, treatment, pathogen culture results, and clinical outcomes were extracted from the electronic records in each hospital, subsequently cross-checked for data accuracy by two independent intensivists. All data were entered into the computerized database for further statistical analyses.

Study definitions

The management of each patient in the ICU was decided upon by the attending physicians, and was mainly in accordance with the Chinese guidelines (11). The decision to conduct microbiological cultivation was also based on the judgment of the attending physician. Specimens included sputum for non-intubated patients and endotracheal aspirates or bronchoscopically obtained samples for intubated or tracheotomy patients, blood, urine, pleural effusion and any other samples acquired from suspected sites of infection. Secondary infection was defined as at least one or more positive culture result among a patient's specimens after ICU admission of more than 72 hours duration.

Study outcomes

The primary outcome measure was the frequency of bacterial and fungal organisms cultured from respiratory tract, blood and other body fluid specimens. We also assessed the risk factors for secondary infection, and the impact of this on clinical outcomes of COVID-19 patients.

Statistical analysis

Descriptive statistics included frequency analysis (percentages) for categorical variables and means (SD) for normally distributed continuous variables, or medians [interquartile range (IQR)] for skewed data. To test for differences, we used two-sample *t*-tests for continuous variables and the χ^2 test for discrete variables. The Kaplan-Meier method was used to depict the probability of survival and to generate survival curves. Variables identified as significant ($P < 0.2$) were entered into a multivariate logistic regression model to investigate the relationship between explanatory variables and the occurrence of secondary infection. All analyses were carried out using SPSS version 10 (IBM Corp, Armonk, NY, USA). A two-sided *P* value of 0.05 was considered to be significant.

Results

During the study period, a total of 190 patients infected with SARS-CoV-2 who met the severe or critical criteria defined by the Chinese guidelines (11) were enrolled. Of the study cohort, 62 patients (32.6%) were female, and the mean age was 62.7 (SD 13.3) years. The majority of patients had underlying comorbidities (140/190, 73.7%). Eleven patients (5.8%) were classified as "severe", while 179 patients (94.2%) were classified as "critical". However, all of them needed respiratory support upon admission to the ICU. *Table 1* describes the patient characteristics in detail.

Among the 190 patients, 1,929 specimens were collected (10.2 specimens per patient on average), and 1,104 positive cultures (57.2%) were obtained. Of these positive cultures, 935 (935/1,104, 84.7%) were from the lower respiratory tract, 131 (131/1,104, 11.9%) were from blood, and 38 (38/1,104, 3.4%) were from other body fluid specimens. The distribution of cultures in the three hospitals is shown in *Table 2*.

Of the study cohort, 165 patients (86.8%) had positive cultures (including bacteria and fungi) after ICU admission of more than 72 hours duration. Of these, 150 patients showed positive sputum/lower respiratory tract aspirate cultures, followed by 64 patients showing positive blood cultures, and 24 patients with positive cultures from other sites (*Table 3*).

Of the 1,104 positive cultures obtained from 165 patients, the most common organisms overall were *Klebsiella pneumoniae* (24.5%), *Acinetobacter baumannii* (21.8%), *Stenotrophomonas maltophilia* (9.9%), *Candida albicans* (6.8%),

Table 1 Baseline patient characteristics

Patient characteristics	No.	Data
Age, mean (SD), years	190	62.68 (13.3)
Gender, female	190	62 (32.6)
Any comorbidity, yes	190	140 (73.7)
Major comorbidities		
Hypertension	190	95 (50.0)
Diabetes	190	40 (21.1)
Cardiopathy	190	30 (15.8)
Malignancy	190	12 (6.32)
Liver cirrhosis	190	3 (1.58)
Cerebrovascular	190	23 (12.1)
Tuberculosis	190	1 (0.5)
Chronic respiratory disease	190	15 (7.9)
Chronic kidney diseases	190	1 (0.5)
Others	190	29 (15.3)
Eligibility criteria for COVID-19		
Severe	190	11 (5.8)
Critical	190	179 (94.2)
Respiratory support on ICU admission		
COT	190	2 (1.1)
HFNC	190	65 (34.2)
NIV	190	52 (27.4)
IMV	190	71 (37.4)

Data are presented as No. (%) unless otherwise noted. SD, standard deviation; COVID-19, coronavirus disease 2019; ICU, intensive care unit; COT, conventional oxygen therapy; HFNC, high flow nasal cannular; NIV, noninvasive ventilation; IMV, invasive mechanical ventilation.

Table 2 Distribution of cultures in three hospitals

Variable	Total (n=190)	Jinyintan Hospital (n=97)	Union West Hospital (n=74)	The 1 st affiliated Hospital of Guangzhou Medical University (n=19)
Inspection frequency	1,929	1,072	440	417
Positive cultures	1,104 (57.2%)	525 (49%)	335 (76.1%)	244 (58.5%)
From lower respiratory tract	935 (84.7%)	414 (78.9%)	289 (86.3%)	232 (95.1%)
From blood	131 (11.9%)	90 (17.1%)	40 (11.9%)	1 (0.4%)
[#] From other body fluid specimens	38 (3.4%)	21 (4%)	6 (1.8%)	11 (4.5%)

[#]Other body fluid specimens included urine, pleural effusion and any other samples acquired from suspected sites of infection.

Table 3 Characteristics of positive bacterial cultures

Characteristics of positive cultures	No.	Data
Any positive culture after ICU admission >72 hours, yes	190	165 (86.8)
Number of positive sputum/lower respiratory tract aspirates cultures per patient, median (IQR)	190	3.0 (1.0–6.0)
Frequency of positive sputum/lower respiratory tract aspirates culture among all positive cultures	150	
1 positive culture		30 (20.0)
2 positive cultures		19 (12.7)
≥3 positive cultures		101 (67.3)
Number of positive blood cultures per patient, median (IQR)	190	0 (0–1.0)
Frequency of positive blood culture among all positive cultures	64	
1 positive culture		32 (50.0)
2 positive cultures		20 (31.2)
≥3 positive cultures		12 (18.8)
[#] Number of other positive cultures per patient, median (IQR)	190	0 (0–0)
Frequency of other positive culture among all positive cultures	24	
1 positive culture		15 (62.5)
2 positive cultures		5 (20.9)
≥3 positive cultures		4 (16.7)

Data are presented as No. (%) unless otherwise noted. [#]Other positive cultures were obtained from urine, pleural effusion and any other samples acquired from suspected sites of infection. ICU, intensive care unit; IQR, interquartile range.

and *Pseudomonas spp.* (4.8%). It was noteworthy that the proportions of multidrug resistant (MDR) bacteria and carbapenem resistant Enterobacteriaceae (CRE) were very high (94.5% in *K. pneumoniae*, 98.3% in *A. baumannii* and 92.5% in *Pseudomonas spp.*). The positive cultures were mainly obtained from sputum and/or lower respiratory tract aspirates. Conversely, only four patients showed six instances of MRSA positivity, all of which were obtained from sputum and/or lower respiratory tract aspirates. More details are shown in *Table 4*. Of the total positive cultures, 525 were from Jinyintan Hospital (47.6%), with the most common organisms being *K. pneumoniae* (29.3%), *A. baumannii* (22.7%), *C. albicans* (10.5%), *Pseudomonas spp.* (5.9%) and *S. maltophilia* (3.6%). A total of 335 were from Union West Hospital, with the most common organisms being (36.1%), *K. pneumoniae* (32.5%), *S. maltophilia* (10.5%), *Pseudomonas spp.* (6.6%) and *Escherichia coli* (3%). The remaining 244 positive samples were from The First Affiliated Hospital of Guangzhou Medical University, and the most common organisms were *S. maltophilia* (22.5%), *Burkholderia cepacia* (12.7%), *Ralstonia pickettii* (4.9%), *K.*

pneumoniae (3.3%) and *C. albicans* (3.3%) (*Figure 1*).

On comparison, patients with positive cultures were older (63.9±12.9 vs. 54.6±14.1 years, P=0.001), had a higher proportion of cardiopathy (18.2% vs. 0, P=0.04), and had a longer duration of mechanical ventilation [15.0 (IQR, 7.5–27.0) vs. 4.0 (IQR, 2.5–5.5), P=0.03] compared with those without secondary infections. Other baseline characteristics were similar. It seemed that more patients with positive cultures received glucocorticoid exceeding 1 mg/kg/day for more than 3 days (73.4% vs. 54.5%, P=0.07) and carbapenem for more than 3 days (49.7% vs. 33.3%, P=0.16) in the week preceding ICU admission. Additionally, more patients with positive cultures received invasive mechanical ventilation upon ICU admission (40% vs. 20%, P=0.05) compared with those patients with negative cultures. However, these differences were not statistically significant (*Table 5*). Finally, the variables identified as significant (P<0.2) were entered into a multivariate logistic regression model to investigate the relationship between explanatory variables and the occurrence of secondary infection, and the result showed

Table 4 Frequency of organisms isolated according to date of acquisition

Pathogens isolated	Total positive (N=1,104)	Patients (N=165)	Frequency of organisms per patients
Gram negative bacteria			
<i>Acinetobacter baumannii</i>	241 (21.8)	78 (47.3)	3.09
MDR- <i>Acinetobacter baumannii</i>	237 (98.3)	76 (97.4)	3.12
Sputum/lower respiratory tract aspirates	225 (94.9)	75 (98.7)	3.00
Blood	9 (3.8)	9 (11.8)	1.00
Other places	3 (1.3)	2 (2.6)	1.00
Non MDR- <i>Acinetobacter baumannii</i>	4 (1.7)	3 (3.8)	1.33
Sputum/lower respiratory tract aspirates	2 (50.0)	2 (66.7)	1.00
Blood	2 (50.0)	1 (33.3)	2.00
Other places	0 (0)	0 (0)	–
<i>Pseudomonas species</i>	53 (4.8)	17 (10.3)	3.31
MDR- <i>Pseudomonas species</i>	49 (92.5)	16 (94.1)	3.06
Sputum/lower respiratory tract aspirates	49 (100.0)	16 (100.0)	3.06
Blood	0 (0)	0 (0)	–
Other places	0 (0)	0 (0)	–
Non MDR- <i>Pseudomonas species</i>	4 (7.5)	2 (11.8)	2.00
Sputum/lower respiratory tract aspirates	4 (100.0)	2 (100.0)	2.00
Blood	0 (0)	0 (0)	–
Other places	0 (0)	0 (0)	–
<i>Klebsiella pneumoniae</i>	271 (24.5)	77 (46.7)	3.52
CRE- <i>Klebsiella pneumoniae</i>	256 (94.5)	74 (96.1)	3.46
Sputum/lower respiratory tract aspirates	221 (86.3)	73 (98.6)	3.03
Blood	34 (13.3)	22 (29.7)	1.55
Other places	1 (0.4)	1 (1.4)	1.00
Non CRE- <i>Klebsiella pneumoniae</i>	15 (5.5)	4 (5.2)	3.75
Sputum/lower respiratory tract aspirates	9 (60.0)	2 (50.0)	4.50
Blood	3 (20.0)	1 (25.0)	3.00
Other places	3 (20.0)	1 (25.0)	3.00
<i>Escherichia coli</i>	19 (1.7)	10 (6.1)	1.90
CRE- <i>Escherichia coli</i>	3 (15.8)	2 (20.0)	1.50
Sputum/lower respiratory tract aspirates	2 (66.7)	1 (50.0)	2.00
Blood	0 (0)	0 (0)	–
Other places	1 (33.3)	1 (50.0)	1.00

Table 4 (continued)

Table 4 (continued)

Pathogens isolated	Total positive (N=1,104)	Patients (N=165)	Frequency of organisms per patients
<i>Non CRE-Escherichia coli</i>	16 (84.2)	8 (80.0)	2.00
Sputum/lower respiratory tract aspirates	15 (93.8)	7 (87.5)	2.14
Blood	0 (0)	0 (0)	–
Other places	1 (6.2)	1 (12.5)	1.00
<i>Stenotrophomonas maltophilia</i>	109 (9.9)	33 (20.0)	3.30
Sputum/lower respiratory tract aspirates	104 (95.4)	32 (97.0)	3.25
Blood	2 (1.8)	2 (6.1)	1.00
Other places	3 (2.8)	3 (9.1)	1.00
<i>Burkholderia cepacia</i>	38 (3.4)	8 (4.8)	4.75
Sputum/lower respiratory tract aspirates	38 (100.0)	8 (100.0)	4.75
Blood	0 (0)	0 (0)	–
Other places	0 (0)	0 (0)	–
Elizabethan enterotoxigenesis of meningitis	1 (0.1)	1 (0.6)	1.00
Sputum/lower respiratory tract aspirates	1 (100.0)	1 (100.0)	1.00
Blood	0 (0)	0 (0)	–
Other places	0 (0)	0 (0)	–
<i>Ralstonia pickettii</i>	12	3 (1.8)	4
Sputum/lower respiratory tract aspirates	12 (100.0)	3 (100.0)	4
Blood	0 (0)	0 (0)	–
Other places	0 (0)	0 (0)	–
<i>Corynebacterium striatum</i>	7 (0.6)	6 (3.6)	1.17
Sputum/lower respiratory tract aspirates	4 (57.1)	4 (66.7)	1.00
Blood	3 (42.9)	2 (33.3)	1.50
Other places	0 (0)	0 (0)	–
<i>Gram positive bacteria</i>			
MRSA	6 (0.5)	4 (2.4)	1.50
Sputum/lower respiratory tract aspirates	6 (100.0)	4 (100.0)	1.50
Blood	0	0 (0)	–
Other places	0	0 (0)	–
Coagulase-negative staphylococci	43 (3.9)	31 (18.8)	1.39
Sputum/lower respiratory tract aspirates	9 (20.9)	6 (19.4)	1.50
Blood	33 (76.7)	26 (83.9)	1.27
Other places	1 (2.3)	1 (3.2)	1.00

Table 4 (continued)

Table 4 (continued)

Pathogens isolated	Total positive (N=1,104)	Patients (N=165)	Frequency of organisms per patients
<i>Enterococcus faecium</i>	20 (1.8)	15 (9.1)	1.33
Sputum/lower respiratory tract aspirates	3 (15.0)	2 (13.3)	1.50
Blood	9 (45.0)	8 (53.3)	1.13
Other places	8 (40.0)	7 (46.7)	1.14
<i>Enterococcus faecalis</i>	3 (0.3)	3 (1.8)	1.00
Sputum/lower respiratory tract aspirates	1 (33.3)	1 (33.3)	1.00
Blood	1 (33.3)	1 (33.3)	1.00
Other places	1 (33.3)	1 (33.3)	1.00
<i>Enterococcus casseliflavus</i>	7 (0.6)	6 (3.6)	1.17
Sputum/lower respiratory tract aspirates	0 (0)	0 (0)	–
Blood	7 (100.0)	6 (100.0)	1.17
Other places	0 (0)	0 (0)	–
Fungus			
<i>Candida albicans</i>	75 (6.8)	60 (36.4)	1.25
Sputum/lower respiratory tract aspirates	69 (92.0)	59 (98.3)	1.17
Blood	5 (6.7)	1 (1.7)	5.00
Other places	1 (1.3)	1 (1.7)	1.00
<i>Non-candida albicans</i>	52 (4.7)	38 (23.0)	1.37
Sputum/lower respiratory tract aspirates	40 (76.9)	32 (84.2)	1.25
Blood	7 (13.5)	5 (13.2)	1.40
Other places	5 (9.6)	4 (10.5)	1.25
<i>Aspergillus</i>	7 (0.6)	4 (2.4)	1.25
Sputum/lower respiratory tract aspirates	7 (100.0)	4 (100.0)	1.75
Blood	0 (0)	0 (0)	–
Other places	0 (0)	0	–

Data are presented as No. (%). MRSA, methicillin-resistant *Staphylococcus aureus*; CRE, carbapenem resistant Enterobacteriaceae; MDR, multidrug resistant. Other places included urine, pleural effusion and any other samples acquired from suspected sites of infection.

that age ≥ 60 years [odds ratio (OR) 4.885; 95% confidence interval (CI), 1.813–13.158] and mechanical ventilation ≥ 13 days (OR 24.759; 95% CI, 3.044–201.383) independently increased the likelihood of secondary infection in severe and critical COVID-19 patients (Table 6).

Patients with positive cultures had fewer ventilator free days in 28 days compared with those with negative cultures (2.2 \pm 5.4 vs. 6.1 \pm 10.8 days, $P=0.02$), while the mortality at 28 days ICU admission was similar (Table 7, Figure 2). However, when the patients were divided into CRE and/

or MDR bacteria-positive and non-CRE and/or MDR bacteria-positive groups, the patients with CRE and/or MDR bacteria positivity showed lower 28 days survival ($P=0.02$; Figure 3).

Discussion

In this work, we evaluate the epidemiology of secondary infections in severe and critical COVID-19 patients. We found that secondary infection was very common (86.6%) in




Figure 1 The distribution of organisms isolated in three hospitals. (A) Distribution of organisms isolated in Jinyintan Hospital. (B) Distribution of organisms isolated in Union West Hospital. (C) Distribution of organisms isolated in The First Affiliated Hospital of Guangzhou Medical University.

this patient population when they were admitted to the ICU for more than 72 hours, and the majority were respiratory infections. The most common organisms isolated overall were *K. pneumoniae* (24.5%), *A. baumannii* (21.8%), *S. maltophilia* (9.9%), *C. albicans* (6.8%), and *Pseudomonas spp.* (4.8%). Furthermore, the proportions of MDR bacteria and CRE were surprisingly high (94.5% in *K. pneumoniae*, 98.3% in *A. baumannii* and 92.5% in *Pseudomonas spp.*). Interestingly, the distribution of organisms isolated was quite different between Wuhan and Guangzhou; the main organisms isolated in Wuhan were *K. pneumoniae* and *A. baumannii*, while *S. maltophilia* and *B. cepacia* were more common in Guangzhou. We also found that age ≥ 60 years and mechanical ventilation ≥ 13 days (OR 24.759; 95% CI, 3.044–201.383) independently increased the likelihood of secondary infection in severe and critical COVID-19 patients. Finally, patients with positive cultures had reduced ventilator free days in 28 days and those with CRE and/or MDR bacteria positivity showed a lower 28-day survival rate.

The coinfection of the SARS-CoV-2 with other microorganisms, which make the diagnosis and treatment

more difficult and contribute to the poor prognosis in COVID-19 patients, is crucial in the management of COVID-19 patients (12). However, the true prevalence of coinfection in such patients remained largely unclear. Sogaard *et al.* observed a high frequency of secondary infections among hospitalized SARS-CoV-2-positive patients. Among 162 SARS-CoV-2-positive hospitalized patients, 31 secondary infections were diagnosed including five viral co-infections, 24 bacterial infections, and three fungal infections, and antibiotic or antifungal treatment was administered in 71 (43.8%) patients. They also found that hospital-acquired bacterial and fungal infections were more frequent among ICU patients than other patients (36.6% *vs.* 1.7%) (13). However, the prevalence of pulmonary microbial co-infections is modest among COVID-19 patients upon admission to ICU in Region Zealand in Denmark (14).

Secondary infection had always been a common concern in the field of critical care medicine worldwide. In 1995, the results of the EPIC study, which evaluated the prevalence of nosocomial infection in ICUs in Europe, demonstrated that 20.6% of ICU patients acquired nosocomial infection

Table 5 Characteristics, treatments, and outcomes of patients with positive cultures compared with those without

Patient variable	^a Overall (n=190)	No positive culture (n=25)	Positive culture (s) (n=165)	P value
Age, mean (SD), y	62.7 (13.3)	54.6 (14.1)	63.9 (12.9)	0.001
Gender, female, No. (%)	62 (32.6)	7 (28.0)	55 (33.3)	0.59
Any comorbidity, yes, No. (%)	140 (73.7)	17 (68.0)	123 (74.6)	0.49
Total No. major comorbidities, mean (SD)	1.36 (1.3)	1.04 (1.0)	1.4 (1.2)	0.13
Hypertension, No. (%)	95 (50.0)	10 (40.0)	85 (51.5)	0.51
Diabetes, No. (%)	40 (21.1)	4 (16.0)	36 (21.8)	0.13
Cardiopathy, No. (%)	30 (15.8)	0 (0.0)	30 (18.2)	0.04
Malignancy, No. (%)	12 (6.3)	1 (4.0)	11 (6.7)	0.94
Liver cirrhosis, No. (%)	3 (1.6)	1 (4.0)	2 (1.2)	0.86
Cerebrovascular, No. (%)	23 (12.1)	2 (8.0)	21 (12.7)	0.73
Tuberculosis, No. (%)	1 (0.5)	0 (0.0)	1 (0.6)	0.27
Chronic respiratory disease, No. (%)	15 (7.9)	1 (4.0)	14 (8.5)	0.71
Chronic kidney diseases, No. (%)	1 (0.5)	1 (4.0)	0 (0.0)	0.27
Others, No. (%)	29 (15.3)	5 (20.0)	24 (14.6)	0.68
Lymphocyte, mean (SD), 10 ⁹	0.73 (0.98)	0.60 (0.41)	0.76 (1.04)	0.45
Neutrophil/Lymphocyte, mean (SD)	23.16 (20.82)	23.15 (15.28)	23.16 (21.58)	0.99
Creatinine, mean (SD), μmol/L	83.71 (71.97)	96.78 (117.97)	80.70 (62.55)	0.30
ALT, mean (SD), U/L	64.65 (148.51)	56.98 (55.78)	64.90 (156.42)	0.80
AST, mean (SD), U/L	62.47 (170.85)	51.68 (40.91)	64.12 (182.75)	0.74
Duration of mechanical ventilation (IQR)	13.0 (6.0–26.3) (n=154)	4.0 (2.5–5.5) (n=15)	15.0 (7.5–27.0) (n=139)	0.003
Severe COVID-19, No. (%)	11 (5.8)	3 (12.0)	8 (4.8)	0.84
Critical COVID-19, No. (%)	179 (94.2)	22 (88.0)	157 (95.2)	0.33
Respiratory support on ICU admission				
COT	2 (1.1)	1 (4.0)	1 (0.6)	0.62
HFNC	65 (34.2)	11 (44.0)	54 (32.7)	0.27
NIV	52 (27.4)	8 (32.0)	44 (26.7)	0.58
IMV	71 (37.4)	5 (20.0)	66 (40.0)	0.05
Glucocorticoid use exceeds 1 mg/kg/day for more than 3 days before ICU admission within 1 week, yes, No. (%)	117 (70.9) (n=165)	12 (54.5) (n=22)	105 (73.4) (n=143)	0.07
Antibiotic use >3 days before ICU admission within 1 week, yes, No. (%)	151 (93.2) (n=162)	9 (81.8) (n=11)	132 (87.4) (n=151)	0.95
Carbapenem, No. (%)	117 (47.5) (n=162)	7 (33.3) (n=21)	70 (49.7) (n=141)	0.16
Beta-lactams, No. (%)	92 (56.8) (n=162)	10 (47.6) (n=21)	82 (58.2) (n=141)	0.36
Carbostyryl No. (%)	102 (63.0) (n=162)	13 (61.9) (n=21)	89 (63.1) (n=141)	0.91
Aminoglycoside, No. (%)	2 (1.2) (n=162)	0 (0) (n=21)	2 (1.4) (n=141)	0.61
Glycopeptide, No. (%)	38 (23.5) (n=162)	5 (26.3) (n=21)	33 (23.4) (n=141)	0.81
Antifungal, No. (%)	24 (14.8) (n=162)	2 (9.5) (n=21)	22 (15.6) (n=141)	0.68

Data are presented as No. (%) unless otherwise noted. ^aTotal sample size is 190. Where data are unavailable, sample size for data is provided. SD, standard deviation; IQR, interquartile range; COVID-19, coronavirus disease 2019; ICU, intensive care unit; COT, conventional oxygen therapy; HFNC, high flow nasal cannular; NIV, noninvasive ventilation; IMV, invasive mechanical ventilation.

Table 6 Independent high risk factors for secondary infection in severe and critical COVID-19 patients upon admission to ICU

Variable	B	Wald	P	OR	95% CI
Age ≥ 60 years	1.436	9.841	0.002	4.885	1.813–13.158
Glucocorticoid use exceeds 1 mg/kg/day for more than 3 days before ICU admission within 1 week	0.808	2.155	0.142	2.244	0.763–6.600
IMV	0.351	0.345	0.557	1.421	0.440–4.592
Carbapenem use >3 days before ICU admission within 1 week	0.054	0.009	0.926	1.056	0.339–3.286
Comorbidity: cardiopathy	0.568	1.223	0.269	1.764	0.645–4.822
Mechanical ventilation ≥ 13 days	3.209	9.005	0.003	24.759	3.044–201.383

OR, odds ratio; 95% CI, 95% confident interval.

Table 7 Impact of secondary infection on clinical outcomes

Patient variable	^a Overall (n=190)	No positive culture (n=25)	Positive cultures (n=165)	P value
Ventilator-free days in 28 days, mean (SD)	2.6 (6.2) (n=154)	6.1 (10.8) (n=15)	2.2 (5.4) (n=139)	0.02
28 days ICU mortality	95 (51.4) (n=185)	12 (50.0) (n=24)	83 (51.6) (n=161)	0.89

Data are presented as No. (%) unless otherwise noted. ^aTotal sample size is 190. Where data are unavailable, sample size for data is provided. SD, standard deviation; ICU, intensive care unit.




Figure 2 Twenty-eight-day ICU Kaplan-Meier survival curve comparing patients without positive cultures to those with positive cultures. $P=0.46$.




Figure 3 Twenty-eight-day ICU Kaplan-Meier survival curve comparing patients with carbapenem resistant Enterobacteriaceae (CRE) and multidrug resistant (MDR) positive cultures with those with non-CRE and MDR positive cultures. $P=0.02$.

and this positively correlated with the mortality rate (15). Even now, in the latest EPIC III study, the incidence of ICU acquired infection, which was with a substantial risk of in-hospital mortality, was 22% (16). In another study that focused on secondary infection in 2009 influenza A (H1N1), positive cultures were obtained in 38% of critically

ill patients who were admitted to the ICU (6). However, the incidence of secondary infection in our study was surprisingly high (86.6%). We thought the main reasons were as follows. First, although a complete nosocomial infection prevention and control system was set up in China

according to the guidelines (17,18), medical staff wore extensive personal protective equipment, and the heavy workload contributed to the incomplete implementation of these measures, especially during the early stage of the pandemic in Wuhan. It is worth noting that only one patient acquired bloodstream infection in The First Affiliated Hospital of Guangzhou Medical University; this was significantly less than the other two hospitals in Wuhan, which might be due to insufficient medical resources in Wuhan. This phenomenon was consistent with the previous opinion that practices to prevent health care-acquired infections were generally absent in low-resource settings (19,20). Second, SARS-CoV-2 induces severe lung damage, damages the respiratory tract epithelium, and causes apoptosis of lung macrophages and neutrophils, thus weakening barrier function (21), ultimately increasing susceptibility to secondary infection in the lung.

Similar to the EPIC III study (16), the majority of the organisms isolated in our study were gram negative bacteria, particularly *K. pneumoniae* and *A. baumannii*. Additionally, we found that the proportions of MDR bacteria and CRE were surprisingly high. CRE and MDR *A. baumannii* emerged as a major worldwide human health threat, as CRE infections are associated with high mortality and morbidity (22-24). In China, CRE and MDR *A. baumannii* represent a rapidly-emerging threat because the isolation rate has recently increased year by year (25), and this microbe reduces patients' clinical outcomes (26). Interestingly, our study found that these pathogens mainly occurred in Wuhan, and the proportions were much lower in Guangzhou. We considered the possibility that many ICUs were improvised in response to a sudden outbreak of the pandemic in Wuhan with a serious shortage of experienced ICU medical staff, and this was likely to be a major contributing factor to the spread of drug-resistant bacteria.

Our study demonstrated that advanced age and long duration of mechanical ventilation were independent high risk factors for secondary infection in severe and critical COVID-19 patients, consistent with previous studies and guidelines (16,17). However, we failed to demonstrate that glucocorticoid and antibiotic usage were independently associated with the occurrence of secondary infections. The main reasons behind this may be that the limited sample size did not have sufficient power to evaluate the true effect and the proportions of glucocorticoid and antibiotic usage in patients both with and without positive cultures were high, which made it more difficult to assess the real effects.

In the EPIC III study, no specific organism was independently associated with a higher risk of death when considering all patients with secondary infections. Elderly age, higher simplified acute physiology score II, and comorbidities of metastatic cancer, HIV infection, and heart failure were independently associated with a higher risk of death. However, this variation was associated with patient- and disease-specific factors, with the process of care and intercountry differences. When considering only antibiotic-resistant organisms, infections with *Klebsiella spp.* resistant to β -lactam antibiotics (including third-generation cephalosporins and carbapenems), and carbapenem-resistant *Acinetobacter spp.* were independently associated with an increased risk of death, highlighting the association of antibiotic resistance with mortality and the importance of good antibiotic stewardship (16). The results of our study also demonstrated that secondary infections decreased ventilator-free days at 28 days, and CRE and MDR bacterial infection decreased the 28-day ICU survival rate, consistent with previous studies (27-30).

Our study has some limitations. Firstly, this is a retrospective study. Selection bias may affect the results, further prospective studies are needed to assess the true incidence of secondary infection in COVID-19 patients. Secondly, the definition of secondary infection is based on the microbiological culture results. The clinical data may not be sufficient to differentiate between infection and colonization in a retrospective study, which may influence the interpretation of frequencies of "secondary infection". However, the result of this study is still reasonably 'representative' and reflected the real situation during the early stage of the COVID-19.

Conclusions

In a retrospective cohort of severe and critical COVID-19 patients admitted to ICUs at the early stage of the COVID-19 pandemic in China, the prevalence of secondary infection was high, particularly CRE and MDR bacteria, resulting in poor clinical outcomes. Prevalence of secondary infection in COVID-19 patients may vary across different regions, which reveal matching of demand and supply of healthcare resources affect the prevalence of secondary infection.

Acknowledgments

Funding: This work was supported by Emergency Key

Program of Guangzhou Laboratory [Grant No. EKPG21-17], The Natural Science Foundation of Guangdong Province, China [2020A1515011459], The Major special projects of the Ministry of Science and Technology [2020YFC0841300] and National Natural Science Foundation of China [81970071 and 82070084].

Footnote

Reporting Checklist: The authors have completed the STROBE reporting checklist. Available at <https://dx.doi.org/10.21037/apm-21-833>

Data Sharing Statement: Available at <https://dx.doi.org/10.21037/apm-21-833>

Peer Review File: Available at <https://dx.doi.org/10.21037/apm-21-833>

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at <https://dx.doi.org/10.21037/apm-21-833>). The authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013). This study was approved separately by the Independence Ethics Committee of Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (Approval No.: 2020-0307), Medical Ethics Committee of Wuhan Infectious Disease Hospital (Approval No.: KY-2020-56.01) and Ethics Committee of the First Affiliated Hospital of Guangzhou Medical University (2020-065). Informed consent was waived due to the retrospective nature of the study.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: <https://creativecommons.org/licenses/by-nc-nd/4.0/>.

References

1. WHO Coronavirus (COVID-19) Dashboard. Available online: <https://covid19.who.int/>. Accessed on 31 March 2021.
2. Richardson S, Hirsch JS, Narasimhan M, et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. *JAMA* 2020;323:2052-9.
3. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet* 2020;395:1054-62.
4. Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. *Lancet Respir Med* 2020;8:475-81.
5. MacIntyre CR, Chughtai AA, Barnes M, et al. The role of pneumonia and secondary bacterial infection in fatal and serious outcomes of pandemic influenza a(H1N1)pdm09. *BMC Infect Dis* 2018;18:637.
6. Muscedere J, Ofner M, Kumar A, et al. The occurrence and impact of bacterial organisms complicating critical care illness associated with 2009 influenza A(H1N1) infection. *Chest* 2013;144:39-47.
7. Yap FH, Gomersall CD, Fung KS, et al. Increase in methicillin-resistant *Staphylococcus aureus* acquisition rate and change in pathogen pattern associated with an outbreak of severe acute respiratory syndrome. *Clin Infect Dis* 2004;39:511-6.
8. Shang Y, Pan C, Yang X, et al. Management of critically ill patients with COVID-19 in ICU: statement from front-line intensive care experts in Wuhan, China. *Ann Intensive Care* 2020;10:73.
9. Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. *JAMA* 2020;323:1061-9.
10. Wu C, Chen X, Cai Y, et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. *JAMA Intern Med* 2020;180:934-43.
11. Diagnosis and Treatment protocol for COVID-19 (Trial Version 7) by National Health Commission & State Administration of Traditional Chinese Medicine. Available online: <http://www.nhc.gov.cn/yzygj/s7653p/202003/46c9294a7dfe4cef80dc7f5912eb1989/files/ce3e6945832a438eaae415350a8ce964.pdf>. Accessed on 4 March 2020.

12. Chen X, Liao B, Cheng L, et al. The microbial coinfection in COVID-19. *Appl Microbiol Biotechnol* 2020;104:7777-85.
13. Søgaard KK, Baettig V, Osthoff M, et al. Community-acquired and hospital-acquired respiratory tract infection and bloodstream infection in patients hospitalized with COVID-19 pneumonia. *J Intensive Care* 2021;9:10.
14. Thomsen K, Pedersen HP, Iversen S, et al. Extensive microbiological respiratory tract specimen characterization in critically ill COVID-19 patients. *APMIS* 2021;129:431-7.
15. Vincent JL, Bihari DJ, Suter PM, et al. The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee. *JAMA* 1995;274:639-44.
16. Vincent JL, Sakr Y, Singer M, et al. Prevalence and Outcomes of Infection Among Patients in Intensive Care Units in 2017. *JAMA* 2020;323:1478-87.
17. Kalil AC, Metersky ML, Klompas M, et al. Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. *Clin Infect Dis* 2016;63:e61-e111.
18. Mermel LA, Allon M, Bouza E, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America. *Clin Infect Dis* 2009;49:1-45.
19. Bebell LM, Muiru AN. Antibiotic use and emerging resistance: how can resource-limited countries turn the tide? *Glob Heart* 2014;9:347-58.
20. Ombelet S, Ronat JB, Walsh T, et al. Clinical bacteriology in low-resource settings: today's solutions. *Lancet Infect Dis* 2018;18:e248-58.
21. Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. *Lancet Respir Med* 2020;8:420-2.
22. Xu L, Sun X, Ma X. Systematic review and meta-analysis of mortality of patients infected with carbapenem-resistant *Klebsiella pneumoniae*. *Ann Clin Microbiol Antimicrob* 2017;16:18.
23. Butler DA, Biagi M, Tan X, et al. Multidrug Resistant *Acinetobacter baumannii*: Resistance by Any Other Name Would Still be Hard to Treat. *Curr Infect Dis Rep* 2019;21:46.
24. Gomez-Simmonds A, Uhlemann AC. Clinical Implications of Genomic Adaptation and Evolution of Carbapenem-Resistant *Klebsiella pneumoniae*. *J Infect Dis* 2017;215:S18-27.
25. Hu F, Guo Y, Zhu D, et al. CHINET 2016 surveillance of bacterial resistance in China. *Chin J Infect Chemother* 2017;17:481-91.
26. Huang W, Qiao F, Zhang Y, et al. In-hospital Medical Costs of Infections Caused by Carbapenem-resistant *Klebsiella pneumoniae*. *Clin Infect Dis* 2018;67:S225-30.
27. Lee NY, Lee HC, Ko NY, et al. Clinical and economic impact of multidrug resistance in nosocomial *Acinetobacter baumannii* bacteremia. *Infect Control Hosp Epidemiol* 2007;28:713-9.
28. Jang TN, Lee SH, Huang CH, et al. Risk factors and impact of nosocomial *Acinetobacter baumannii* bloodstream infections in the adult intensive care unit: a case-control study. *J Hosp Infect* 2009;73:143-50.
29. Asim P, Naik NA, Muralidhar V, et al. Clinical and economic outcomes of *Acinetobacter* vis a vis non-*Acinetobacter* infections in an Indian teaching hospital. *Perspect Clin Res* 2016;7:28-31.
30. Sunenshine RH, Wright MO, Maragakis LL, et al. Multidrug-resistant *Acinetobacter* infection mortality rate and length of hospitalization. *Emerg Infect Dis* 2007;13:97-103.

Cite this article as: Sang L, Xi Y, Lin Z, Pan Y, Song B, Li CA, Zheng X, Zhong M, Jiang L, Pan C, Zhang W, Lv Z, Xia J, Chen N, Wu W, Xu Y, Chen S, Liu D, Liang W, Liu X, Liu X, Li S, Zhong N, Ye D, Xu Y, Zhang N, Zhang D, Li Y. Secondary infection in severe and critical COVID-19 patients in China: a multicenter retrospective study. *Ann Palliat Med* 2021;10(8):8557-8570. doi: 10.21037/apm-21-833